Skip to main content
SpringerLink
Log in

Significance of Bio-intact PTH(1–84) assay in hemodialysis patients

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

The aim of the present study was to examine whether the newly developed bio-intact parathyroid hormone (Bio-PTH) assay, which exclusively measures the intact PTH(1–84) molecule, provides a better assay for estimating parathyroid function in hemodialysis (HD) patients, and to evaluate the factors associated with serum PTH levels measured by Bio-PTH assay and by second-generation intact PTH (I-PTH) assay. The study also examined whether Bio-PTH/I-PTH ratio, an index of the active fraction of PTH, could provide information not obtainable from simple PTH results. Serum levels of PTH were measured in 177 male HD patients, together with the bone formation markers bone alkaline phosphatase (BAP), intact osteocalcin (iOC), N-midfragment osteocalcin (N-Mid OC), and N-terminal propeptide of type I collagen (PINP), and the bone resorption markers deoxypyridinoline (DPD), pyridinoline (PYD), and β-CrossLaps (β-CTx). Bone mineral density (BMD) was determined twice at distal radius one-third by dual-energy X-ray absorptiometry. Serum Bio-PTH was significantly elevated in HD patients compared to normal controls. Serum Bio-PTH and I-PTH correlated significantly in a positive manner with serum bone formation markers (BAP, iOC, N-Mid OC, PINP), and resorption markers (DPD, PYD, β-CTx), and in a negative manner with BMD and annual change therein at distal radius one-third. The degree of correlation of Bio-PTH was not significantly different from that of I-PTH. The Bio-PTH/I-PTH ratio was significantly lower in HD patients than in normal individuals, due probably to accumulation of N-truncated PTH fragments in the former. The Bio-PTH/I-PTH ratio correlated significantly in a negative manner with serum calcium (Ca) (r=−0.251, P<0.001) and nutritional marker serum urea nitrogen, protein catabolic rate and serum creatinine. Multiple regression analysis further revealed that serum I-PTH, but not Bio-PTH, was significantly associated with each of these nutritional markers, and that the Bio-PTH/I-PTH ratio was negatively associated with serum Ca. It was also found that I-PTH, but not Bio-PTH, was influenced by nutritional state. It is concluded that serum Bio-PTH assay could be of similar value to I-PTH assay in evaluating parathyroid function in HD patients and that their combined use in the form of the Bio-PTH/I-PTH ratio could provide information not obtainable from simple PTH results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D’Amour P (1998) A non-(1–84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805–809

    CAS  PubMed  Google Scholar 

  2. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D’Amour P (1996) Accumulation of a non-(1–84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 81:3923–3929

    Article  CAS  PubMed  Google Scholar 

  3. Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, D’Amour P (2000) Influence of glomerular filtration rate on non-(1–84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 46:697–703

    CAS  PubMed  Google Scholar 

  4. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A (2000) A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753–761

    Article  CAS  PubMed  Google Scholar 

  5. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D’Amour P (2001) Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142:1386-1392

    Article  CAS  PubMed  Google Scholar 

  6. Langub MC, Monier-Faugere M-C, Wang G, Williams JP, Koszewski NJ, Malluche HH (2003) Administration of PTH-(7–84) antagonizes the effects of PTH-(1–84) on bone in rats with moderate renal failure. Endocrinology 144:1135–1138

    Article  CAS  PubMed  Google Scholar 

  7. Divieti P, John MR, Juppner H, Bringhurst FR (2002) Human PTH-(7–84) inhibits bone resorption in vitro via actions independent of the type I-PTH/PTHrP receptor. Endocrinology 143:171–176

    Article  CAS  PubMed  Google Scholar 

  8. Segre GV, Niall HD, Habener JF, Potts JT Jr (1974) Metabolism of parathyroid hormone: physiological and clinical significance. Am J Med 56:774–784

    Article  CAS  PubMed  Google Scholar 

  9. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, Gao P, Cantor T, D’Amour P (2002) Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 147:123–131

    CAS  PubMed  Google Scholar 

  10. D’Armour P, Lazure C (1985) Metabolism of radioiodinated carboxyterminal fragments of bovine parathyroid hormone in normal and anephric rats. Endocrinology 117:127–134

    PubMed  Google Scholar 

  11. Mayer GP, Keaton JA, Hurst JG, Habener JF (1979) Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood. Endocrinology 104:1778–1784

    CAS  PubMed  Google Scholar 

  12. Watson PH, Hanley DA (1993) Parathyroid hormone: regulation of synthesis and secretion. Clin Invest Med 16:58–77

    CAS  PubMed  Google Scholar 

  13. Quarles LD, Lobaugh B, Murphy G (1992) Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145–150

    Article  CAS  PubMed  Google Scholar 

  14. Inaba M, Nakatuska K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, Nishizawa Y (2004) Technical and clinical characterization of the Bio-PTH (1–84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 50:385–390

    Article  CAS  PubMed  Google Scholar 

  15. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Juppner H (1999) A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287–4290

    Article  CAS  PubMed  Google Scholar 

  16. Gao P, Scheibel S, D’Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1–84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605–614

    CAS  PubMed  Google Scholar 

  17. Ishimura E, Okuno S, Kim M, Yamamoto T, Izumotani T, Otoshi T, Shoji T, Inaba M, Nishizawa Y (2001) Increasing body fat mass in the first year of hemodialysis. J Am Soc Nephrol 12:1921–1926

    CAS  PubMed  Google Scholar 

  18. Inaba M, Morii H, Katsumata T, Goto H, Ishimura E, Kawagishi T, Kamao M, Okano T, Nishizawa Y (2000) Hyperparathyroidism is augmented by ovariectomy in Nagase analbuminemic rats. J Nutr 130:1543–1547

    CAS  PubMed  Google Scholar 

  19. Inaba M, Nishizawa Y, Mita K, Kumeda Y, Emoto M, Kawagishi T, Ishmura E, Nakatsuka K, Shioi A, Morii H (1999) Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporos Int 9:525–531

    Article  CAS  PubMed  Google Scholar 

  20. Inaba M, Terada M, Nishizawa Y, Shioi A, Ishimura E, Otani S, Morii H (1999) Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism. Metabolism 48:904–909

    CAS  PubMed  Google Scholar 

  21. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y (2000) Persistent increase in bone turnover in Graves’ patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85:4157–4161

    Article  CAS  PubMed  Google Scholar 

  22. Gomes B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560–1566

    CAS  PubMed  Google Scholar 

  23. Takahashi M, Kushida K, Nagano A, Inoue T (2000) Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta 294:67–76

    Article  CAS  PubMed  Google Scholar 

  24. Nagasue K, Inaba M, Okuno S, Kitatani K, Imanishi Y, Ishimura E, Miki T, Kim M, Nishizawa Y (2003) Serum N-terminal midfragment vs. intact osteocalcin immunoradiometric assay as markers for bone turnover and bone loss in hemodialysis patients. Biomed Pharmacother 57:98–104

    CAS  PubMed  Google Scholar 

  25. Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, Shimizu M, Kim M, Nishizawa Y (2002) Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 40:802–809

    Article  CAS  PubMed  Google Scholar 

  26. Inaba M, Nagasue K, Okuno S, Ueda M, Kumeda Y, Imanishi Y, Shoji T, Ishimura E, Ohta T, Nakatani T, Kim M, Nishizawa Y (2002) Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 39:1261–1269

    Article  CAS  PubMed  Google Scholar 

  27. Furumitsu Y, Inaba M, Yukioka K, Yukioka M, Kumeda Y, Azuma Y, Ohta T, Ochi T, Nishizawa Y, Morii H (2000) Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis. J Rheumatol 27:64–70

    CAS  PubMed  Google Scholar 

  28. Niwa T, Shiobara K, Hamada T, Miyazaki T, Tsukushi S, Uema K, Tsuzuki T (1995) Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. Clin Chim Acta 235:33–40

    Article  CAS  PubMed  Google Scholar 

  29. Okabe R, Nakatsuska K, Inaba M, Miki T, Naka H, Masaki H, Moriguchi A, Nishizawa Y (2001) Clinical evaluation of the Elecsys β-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem 47:1410–1414

    CAS  PubMed  Google Scholar 

  30. Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y (2004) Significance of serum CrossLaps as a predictor for changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 22:127–131

    Article  CAS  PubMed  Google Scholar 

  31. Avram MM, Mittman N, Myint MM, Fein P (2001) Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 38:1351–1357

    CAS  PubMed  Google Scholar 

  32. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Juppner H (2003) Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63:1801–1808

    CAS  PubMed  Google Scholar 

  33. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH (2001) Improved assessment of bone turnover by the PTH-(1–84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460–1468

    Article  CAS  PubMed  Google Scholar 

  34. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, Fischer MS, Lifrieri F. Manni M, Morosetti M, Moscaritolo E, Sardella (2002) PTH 1–84 and PTH “7–84” in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 40:348–354

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan

    Masaaki Inaba, Yasuo Imanishi, Misako Ueda, Eiji Ishimura & Yoshiki Nishizawa

  2. Shirasagi Hospital, 7-11-23 Kumata, Higashisumiyoshi-ku, Osaka, Japan

    Senji Okuno & Tomoyuki Yamakawa

Authors
  1. Masaaki Inaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Senji Okuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuo Imanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Misako Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoyuki Yamakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eiji Ishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshiki Nishizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaaki Inaba.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Inaba, M., Okuno, S., Imanishi, Y. et al. Significance of Bio-intact PTH(1–84) assay in hemodialysis patients. Osteoporos Int 16, 517–525 (2005). https://doi.org/10.1007/s00198-004-1715-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-004-1715-1

Keywords

Search

Navigation